Semaglutide vs Tirzepatide: Complete 2026 Comparison

Two GLP-1 drugs have taken over the weight-loss conversation, and the question almost everyone eventually asks is: which one actually works better? The short answer is that tirzepatide produces more total weight loss in head-to-head data. The longer answer is that "better" depends on your starting point, your tolerance for side effects, and what you're willing to pay.

Here is everything you need to make that call.

How each drug works

Both drugs mimic natural gut hormones that regulate appetite and blood sugar, but they hit different receptor targets.

Semaglutide is a GLP-1 receptor agonist. It activates the glucagon-like peptide-1 receptor, which slows gastric emptying, reduces appetite signals in the hypothalamus, and improves insulin sensitivity. One injection per week. The GLP-1 pathway has solid decades of clinical data behind it.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both the GIP receptor and the GLP-1 receptor in a single molecule. GIP (glucose-dependent insulinotropic polypeptide) handles energy expenditure and fat cell metabolism on top of what the GLP-1 axis provides. That second pathway is why the weight loss numbers are consistently higher.

The practical implication: if you plateau on semaglutide, that plateau often reflects maximal GLP-1 receptor saturation. Adding GIP agonism with tirzepatide activates a second independent mechanism, which is why many people who switch see renewed progress.

Side-by-side comparison

Weight loss efficacy in detail

The defining trial is SURMOUNT-5, published in late 2025, which put semaglutide and tirzepatide head-to-head in a randomized controlled trial for the first time. At 72 weeks, tirzepatide produced 10.1 percentage points more weight loss than semaglutide. That is not a marginal difference.

In the individual program trials, STEP 1 (semaglutide) showed ~15% body weight reduction at 2.4 mg/week. The SURMOUNT-1 trial (tirzepatide) showed ~22% at 15 mg/week. The mechanism difference explains the gap: GIP receptor activation improves basal metabolic rate and fat oxidation in ways that GLP-1 alone does not.

That said, 15% body weight loss on semaglutide is still clinically significant. For someone who needs to lose 40 lbs, semaglutide gets most of the job done. Tirzepatide is not categorically necessary unless you have a larger goal, are a non-responder to semaglutide, or want to maximize results.

Side effects

Both drugs share the same GI side effect profile because they both activate the GLP-1 receptor. The most common are nausea, vomiting, diarrhea, and constipation, typically worst in the first 4-8 weeks as your dose titrates up. Slow titration (starting at the lowest dose and increasing every 4 weeks) dramatically reduces severity.

Tirzepatide's higher doses can produce slightly more pronounced early nausea compared to semaglutide's maximum, but this largely disappears once the body adapts. The side effect profiles are close enough that they should not be the deciding factor between the two.

Both share the class-wide risk of gastroparesis at high doses, potential thyroid C-cell changes (relevant only at pharmacological doses over long periods), and injection site reactions.

Who should choose semaglutide

• Starting GLP-1 therapy for the first time: the longer evidence track record and slightly gentler GI impact at lower doses makes it a reasonable first step
• Moderate weight loss goal (10-15% of body weight): semaglutide handles this reliably
• Budget constraints: compounded semaglutide has historically been more available, though that window is closing
• Established prescribing relationship on Ozempic for type 2 diabetes management

Who should choose tirzepatide

• Plateaued on semaglutide: switching activates the GIP pathway and restarts loss
• Higher weight loss goal (20%+ of body weight)
• Type 2 diabetes with insulin resistance: the GIP component has better data for insulin sensitization
• Non-responders to pure GLP-1 agonism: a meaningful subset of people respond much better to dual agonism

2026 regulatory context

The compounded GLP-1 pathway is closing. The FDA's 503B compounding exclusion process for semaglutide has already resulted in enforcement actions, and a comment period closing around June 29-30, 2026 may extend restrictions. Tirzepatide faces a similar trajectory. If you have been sourcing compounded versions, now is the time to evaluate a prescriber relationship for branded product or investigate research-grade vendors carefully.

For research use, peptide bureau's vendor scorecard covers which research peptide companies carry verified GLP-1 agonists with COA documentation. See the vendor page for current rankings.

Cost comparison in practice

Brand-name prices are nearly identical, both in the $900-$1,300/month range without insurance. Many commercial insurance plans now cover Zepbound (tirzepatide for obesity) and Wegovy (semaglutide for obesity), making the out-of-pocket gap smaller than it appears.

GoodRx and manufacturer savings programs can bring brand costs down significantly for commercially insured patients. The research-grade market for both compounds has tightened with regulatory pressure, so historical pricing comparisons may not hold.

For a more detailed cost breakdown by source type, see the tirzepatide cost guide and semaglutide cost without insurance.

What about retatrutide?

Worth a brief mention: retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon receptor agonist now in Phase 3 trials. TRIUMPH-1 Phase 3 data from May 2026 showed 28.3% mean body weight reduction, significantly higher than either drug here. It is not yet approved, and compounded versions are investigational. But if the question is "what comes after tirzepatide plateaus," retatrutide is the likely answer. See the retatrutide guide for protocol details.

The bottom line

Tirzepatide produces more weight loss. Semaglutide has a longer evidence track record. Both are effective, both have similar side effect profiles, and both are facing tighter compounding restrictions in 2026. If you are starting fresh, either is a reasonable choice. If you have plateaued on semaglutide, switch to tirzepatide. If your goal requires 20%+ body weight reduction, start with tirzepatide.

The peptide bureau stack builder includes a weight-loss protocol builder that maps your goal against the evidence for each option.